Physician profile
Grace G Lessing
NPI 1588733141
$1,932.08
in general payments reported to CMS, 2019-2025
18 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.57 · 2020: $56.81 · 2021: $236 · 2022: $332 · 2023: $393 · 2024: $436 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.25 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $646.39 | 2020-2025 | |
| Alcon Vision LLC | $331.66 | 2022-2025 | Simbrinza, Clareon, Tryptyr |
| Allergan, INC. | $195.81 | 2019-2022 | |
| Oyster Point Pharma, INC. | $189.84 | 2022-2024 | Tyrvaya |
| New World Medical,INC. | $118.12 | 2023 | |
| Amgen INC. | $98.72 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.07 | 2020-2021 | |
| Harrow Eye, LLC | $54.62 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $52.00 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Kala Pharmaceuticals, INC. | $28.58 | 2021 | |
| Apellis Pharmaceuticals, INC. | $23.86 | 2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $23.77 | 2019 | |
| Shire North American Group INC | $22.37 | 2019 | |
| Sight Sciences, INC. | $21.51 | 2022 | |
| Horizon Therapeutics Plc | $16.53 | 2023 | Tepezza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $16.48 | 2021 | |
| Sun Pharmaceutical Industries INC. | $16.21 | 2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $14.54 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Lessing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.